Associate Health Minister David Seymour and Health Minister Simeon Brown are pleased that hundreds of thousands of New Zealanders are set to benefit from access to more than 60 medicines, following ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

Shares of Mural Oncology MURA skyrocketed 134% on Tuesday after the company announced its decision to discontinue all ...

Mural Oncology is halting development of its lead IL-2 therapy and enacting major layoffs after its second trial failure this ...

The market is characterized by trends such as personalized medicine, targeted therapies, and combination treatments. Key players include Eli Lilly, B ...

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

The decision to choose systemic adjuvant therapy warrants careful discussion on its benefits and risks,” researchers wrote.

In the trial, researchers are evaluating Scancell's DNA cancer vaccines SCIB1 and iSCIB1+ alongside immunotherapy.

A biotech company based out of Ireland saw its shares soar on Tuesday after the company announced that it is discontinuing ...

Enriqueta Felip, MD, PhD, discusses the design of the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab in ...

Updated phase 3 data support pembrolizumab plus concurrent chemoradiotherapy as a standard of care for patients with high-risk, locally advanced cervical cancer, according to Linda Duska, MD.

Cancer treatments can instigate ocular surface disease and other deleterious ocular side effects that optometrists can oversee and manage.